UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of acoustic emission to identify novel candidate biomarkers for knee osteoarthritis (OA)

PloS one, 2019-10, Vol.14 (10), p.e0223711-e0223711

2019

Volltextzugriff (PDF)

Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran

Statistics in medicine, 2014-07, Vol.33 (17), p.2914-2923

Southworth, Harry

2014

Volltextzugriff (PDF)

067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

BMJ neurology open, 2021-08, Vol.3 (Suppl 1), p.A24-A25

2021

Volltextzugriff (PDF)

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2021-02, Vol.160 (3), p.S8-S9

2021

Volltextzugriff (PDF)

Good Signal Detection Practices: Evidence from IMI PROTECT

Drug safety, 2016-06, Vol.39 (6), p.469-490

2016

Volltextzugriff (PDF)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

European journal of neurology, 2021-11, Vol.28 (11), p.3722-3730

2021

Volltextzugriff (PDF)

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

Inflammatory bowel diseases, 2021-01, Vol.27 (Supplement_1), p.S6-S6

2021

Volltextzugriff (PDF)

Effect of the DP2 antagonist, GB001, on asthma worsening in patients with mild-moderate asthma

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB20

2020

Volltextzugriff (PDF)

Statistical Analysis of Cumulative Serious Adverse Event Data From Development Safety Update Reports

Therapeutic innovation & regulatory science, 2016-03, Vol.50 (2), p.188-194

2016

Volltextzugriff (PDF)

Ozanimod (RPC1063) Reduces Plasma Levels of Neurofilament Light Chain (NfL) in Patients With Relapsing Multiple Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, Phase 2 Study (P3.395)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Effet d’ozanimod sur les proportions des sous-groupes de leucocytes chez les patients atteints de sclérose en plaques récurrente (SEP-R)

Revue neurologique, 2021-04, Vol.177, p.S109-S109

2021

Volltextzugriff (PDF)

Detecting Outliers in Multivariate Laboratory Data

Journal of biopharmaceutical statistics, 2008-01, Vol.18 (6), p.1178-1183

Southworth, Harry

2008

Volltextzugriff (PDF)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

Neurology : neuroimmunology & neuroinflammation, 2020-09, Vol.7 (5), p.e839-e839

2020

Volltextzugriff (PDF)

Extreme value modelling of laboratory safety data from clinical studies

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2012-09, Vol.11 (5), p.361-366

2012

Volltextzugriff (PDF)

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

The American heart journal, 2002-12, Vol.144 (6), p.1044-1051

2002

Volltextzugriff (PDF)

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

The American journal of cardiology, 2003-12, Vol.92 (11), p.1287-1293

2003

Volltextzugriff (PDF)

Multivariate extreme value modelling of laboratory safety data from clinical studies

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2012-09, Vol.11 (5), p.367-372

2012

Volltextzugriff (PDF)

Models for the analysis of C-reactive protein in statin trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2009-04, Vol.8 (2), p.87-97

2009

Volltextzugriff (PDF)

Simulating Titration to Goal Clinical Trials with Statins

Journal of biopharmaceutical statistics, 2004-12, Vol.14 (2), p.451-467

Southworth, Harry

2004

Volltextzugriff (PDF)

Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome

The American journal of cardiology, 2003-03, Vol.91 (5), p.25-27

2003

Volltextzugriff (PDF)

Efficacy of rosuvastatin 10mg in patients with the metabolic syndrome

The American journal of cardiology, 2003-03, Vol.91 (5A), p.C25

2003

Volltextzugriff (PDF)

The Analysis of Safety Data from Clinical Trials

Extreme Value Modeling and Risk Analysis, 2016, p.481-494

2016

Volltextzugriff (PDF)

Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin

Heart, lung & circulation, 2003, Vol.12 (2), p.A41-A41

2003

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Sprache

Englisch
(29)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Humans
(12)
Life Sciences & Biomedicine
(12)
Clinical Trials
(7)
Pharmacology & Pharmacy
(6)
Physical Sciences
(6)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(5)
Mathematics
(5)
Statistics & Probability
(5)
Treatment Outcome
(5)
Female
(4)
Fluorobenzenes - Therapeutic Use
(4)
Male
(4)
Models, Statistical
(4)
Rosuvastatin Calcium
(4)
Adult
(3)
Aged
(3)
Biological And Medical Sciences
(3)
Biomarkers
(3)
Cardiac & Cardiovascular Systems
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of acoustic emission to identify novel candidate biomarkers for knee osteoarthritis (OA)

Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran

067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

Good Signal Detection Practices: Evidence from IMI PROTECT

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

Effect of the DP2 antagonist, GB001, on asthma worsening in patients with mild-moderate asthma

Statistical Analysis of Cumulative Serious Adverse Event Data From Development Safety Update Reports

Ozanimod (RPC1063) Reduces Plasma Levels of Neurofilament Light Chain (NfL) in Patients With Relapsing Multiple Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, Phase 2 Study (P3.395)

Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006)

Effet d’ozanimod sur les proportions des sous-groupes de leucocytes chez les patients atteints de sclérose en plaques récurrente (SEP-R)

Detecting Outliers in Multivariate Laboratory Data

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

Extreme value modelling of laboratory safety data from clinical studies

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

Multivariate extreme value modelling of laboratory safety data from clinical studies

Models for the analysis of C-reactive protein in statin trials

Simulating Titration to Goal Clinical Trials with Statins

Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome

Efficacy of rosuvastatin 10mg in patients with the metabolic syndrome

The Analysis of Safety Data from Clinical Trials

Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin

Suchergebnisse filtern